metformin has been researched along with Colitis in 11 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin, traditionally regarded as a hypoglycemic drug, has been studied in other various fields including inflammation." | 8.02 | Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt. ( Sun, KY; Xiong, W; Zhang, X; Zhou, YH; Zhu, Y; Zou, X, 2021) |
| "Metformin or/and α-LA attenuated the severity of the DSS-induced colitis through improving the reductions in body weights, the DAI, the colonic oxidative stress markers, TNF-α, and NF-κB levels, and the morphological mucosal damage scores." | 7.88 | New insights on the modulatory roles of metformin or alpha-lipoic acid versus their combination in dextran sulfate sodium-induced chronic colitis in rats. ( Elaidy, SM; Essawy, SS; Hassan, MS; Samman, FS, 2018) |
| "These results indicate that metformin suppresses NF-κB activation in intestinal epithelial cells and ameliorates murine colitis and colitis-associated tumorigenesis in mice, suggesting that metformin could be a potential therapeutic agent for the treatment of inflammatory bowel disease." | 7.80 | Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer. ( Kim, IK; Kim, JM; Kim, JS; Ko, SH; Koh, SJ, 2014) |
| "Ulcerative colitis is an inflammatory condition of the colon." | 5.62 | Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling. ( Liu, X; Sun, Z; Wang, H, 2021) |
| "Metformin, traditionally regarded as a hypoglycemic drug, has been studied in other various fields including inflammation." | 4.02 | Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt. ( Sun, KY; Xiong, W; Zhang, X; Zhou, YH; Zhu, Y; Zou, X, 2021) |
| "Metformin or/and α-LA attenuated the severity of the DSS-induced colitis through improving the reductions in body weights, the DAI, the colonic oxidative stress markers, TNF-α, and NF-κB levels, and the morphological mucosal damage scores." | 3.88 | New insights on the modulatory roles of metformin or alpha-lipoic acid versus their combination in dextran sulfate sodium-induced chronic colitis in rats. ( Elaidy, SM; Essawy, SS; Hassan, MS; Samman, FS, 2018) |
| "These results indicate that metformin suppresses NF-κB activation in intestinal epithelial cells and ameliorates murine colitis and colitis-associated tumorigenesis in mice, suggesting that metformin could be a potential therapeutic agent for the treatment of inflammatory bowel disease." | 3.80 | Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer. ( Kim, IK; Kim, JM; Kim, JS; Ko, SH; Koh, SJ, 2014) |
| "Ulcerative colitis is an inflammatory condition of the colon." | 1.62 | Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling. ( Liu, X; Sun, Z; Wang, H, 2021) |
| "Metformin has unexpected beneficial effects other than glucose-lowering effects." | 1.48 | Metformin protects against intestinal barrier dysfunction via AMPKα1-dependent inhibition of JNK signalling activation. ( Chen, Y; Deng, J; Lai, X; Li, J; Lin, Q; Liu, L; Zeng, L, 2018) |
| "Using HCT-116 human colon cancer cell line, expression of AMPK, extracellular signal-regulated kinase (ERK), cyclin D1, and Bcl-2 was investigated and cell cycle arrest was assessed." | 1.46 | Combination of metformin and VSL#3 additively suppresses western-style diet induced colon cancer in mice. ( Byeon, JS; Cho, EA; Chung, EJ; Do, EJ; Hwang, SW; Kim, DH; Kim, JH; Kim, SY; Lee, HJ; Myung, SJ; Pak, S; Park, SH; Yang, DH; Yang, SK; Ye, BD, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Xiong, W | 1 |
| Sun, KY | 1 |
| Zhu, Y | 1 |
| Zhang, X | 1 |
| Zhou, YH | 1 |
| Zou, X | 1 |
| Takahara, M | 1 |
| Takaki, A | 1 |
| Hiraoka, S | 1 |
| Takei, K | 1 |
| Yasutomi, E | 1 |
| Igawa, S | 1 |
| Yamamoto, S | 1 |
| Oka, S | 1 |
| Ohmori, M | 1 |
| Yamasaki, Y | 1 |
| Inokuchi, T | 1 |
| Kinugasa, H | 1 |
| Harada, K | 1 |
| Udono, H | 1 |
| Okada, H | 1 |
| Olivier, S | 1 |
| Diounou, H | 1 |
| Pochard, C | 1 |
| Frechin, L | 1 |
| Durieu, E | 1 |
| Foretz, M | 1 |
| Neunlist, M | 1 |
| Rolli-Derkinderen, M | 1 |
| Viollet, B | 1 |
| Saber, S | 1 |
| El-Kader, EMA | 1 |
| Liu, X | 1 |
| Sun, Z | 1 |
| Wang, H | 1 |
| Deng, J | 1 |
| Zeng, L | 1 |
| Lai, X | 1 |
| Li, J | 1 |
| Liu, L | 1 |
| Lin, Q | 1 |
| Chen, Y | 1 |
| Samman, FS | 1 |
| Elaidy, SM | 1 |
| Essawy, SS | 1 |
| Hassan, MS | 1 |
| Wang, SQ | 1 |
| Cui, SX | 1 |
| Qu, XJ | 1 |
| Koh, SJ | 1 |
| Kim, JM | 1 |
| Kim, IK | 1 |
| Ko, SH | 1 |
| Kim, JS | 1 |
| Chung, EJ | 1 |
| Do, EJ | 1 |
| Kim, SY | 1 |
| Cho, EA | 1 |
| Kim, DH | 1 |
| Pak, S | 1 |
| Hwang, SW | 1 |
| Lee, HJ | 1 |
| Byeon, JS | 1 |
| Ye, BD | 1 |
| Yang, DH | 1 |
| Park, SH | 1 |
| Yang, SK | 1 |
| Kim, JH | 1 |
| Myung, SJ | 1 |
| Gould, M | 1 |
| Sellin, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis[NCT04750135] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-02-07 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for metformin and Colitis
| Article | Year |
|---|---|
Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt.
Topics: 4-Butyrolactone; Animals; Cell Membrane; Colitis; Dextran Sulfate; Down-Regulation; Enzyme Activatio | 2021 |
Metformin ameliorates chronic colitis in a mouse model by regulating interferon-γ-producing lamina propria CD4
Topics: Adoptive Transfer; AMP-Activated Protein Kinases; Animals; CD4-Positive T-Lymphocytes; Colitis; Colo | 2022 |
Intestinal Epithelial AMPK Deficiency Causes Delayed Colonic Epithelial Repair in DSS-Induced Colitis.
Topics: AMP-Activated Protein Kinases; Animals; Colitis; Dextran Sulfate; Disease Models, Animal; Metformin; | 2022 |
Novel complementary coloprotective effects of metformin and MCC950 by modulating HSP90/NLRP3 interaction and inducing autophagy in rats.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Autophagy; Colitis; Dextran Sulfate; Disease M | 2021 |
Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling.
Topics: Animals; Colitis; Cytokines; Disease Models, Animal; Metformin; Mice; Mice, Inbred C57BL; T-Lymphocy | 2021 |
Metformin protects against intestinal barrier dysfunction via AMPKα1-dependent inhibition of JNK signalling activation.
Topics: Acute Disease; Adenylate Kinase; Animals; Bacterial Translocation; Caco-2 Cells; Colitis; Dextran Su | 2018 |
New insights on the modulatory roles of metformin or alpha-lipoic acid versus their combination in dextran sulfate sodium-induced chronic colitis in rats.
Topics: Animals; Antioxidants; Body Weight; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Male; M | 2018 |
Metformin inhibited colitis and colitis-associated cancer (CAC) through protecting mitochondrial structures of colorectal epithelial cells in mice.
Topics: Animals; Colitis; Colonic Neoplasms; Disease Models, Animal; Epithelial Cells; Humans; Hypoglycemic | 2019 |
Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Colitis; Colonic Neoplasms; Dextran Sulfat | 2014 |
Combination of metformin and VSL#3 additively suppresses western-style diet induced colon cancer in mice.
Topics: AMP-Activated Protein Kinases; Animals; Carcinogenesis; Cell Proliferation; Colitis; Colonic Neoplas | 2017 |
Diabetic diarrhea.
Topics: Algorithms; Antidiarrheals; Celiac Disease; Clonidine; Colitis; Diabetes Complications; Diabetes Mel | 2009 |